12-14 Pharmacy Install Monitoring System to Protect Stock After Using ADM Mapping Services

ADM started working with 12-14 Pharmacy Ltd since January 2020, when they were at the early stages of installing their warehouse in their new building.

Over this year we have carried out a winter and Summer Mapping of their warehouse, fridges and delivery vehicles. We provided data and reports to allow the staff at 12-14 Pharmacy Ltd to make adjustments to their processes to ensure all products were kept in the correct environments.

Because 12-14 Pharmacy are happy with our mapping services and support, they decided to install our Temperature Monitoring System called GeneSysWeb. Which provides live and historical temperature reports with alarms to allow remedial actions to be taken to protect stock.

Its imperative that 12-14 Pharmacy store products in controlled environments in their pharmaceutical warehouse, if not this can lead to loss of stock, which can disastrous and expensive.

The GeneSysWeb Temperature Monitoring Solution allows 12-14 Pharmacy to constantly monitor temperatures across the warehouse including fridges and receive alarms should these temperatures change into unsafe preset limits

Working with appointed the staff at 12-14 Pharmacy and their mapping reports, we installed the sensors in the areas needed to give them piece of mind that every area of the site was covered.

Having the GeneSysWeb Temperature Monitoring Solution also helps them be complaint with the MHRA Standards they must follow.

Do you have a pharmaceutical warehouse that requires Mapping or Monitoring?

Our team is on hand to discuss your Mapping or Monitoring requirements, we can help with our many years of experience and reliable range of solutions.

Use the Live Chat to talk to us us now or send an email to info@a-d-m.co.uk

What does the MHRA say about Temperature Mapping and Monitoring?

“An initial temperature mapping exercise should be carried out on the storage area before use, under representative conditions.

Temperature monitoring equipment should be located according to the results of the mapping exercise, ensuring that monitoring devices are positioned in the areas that experience the extremes of fluctuations.

The mapping exercise should be repeated according to the results of a risk assessment exercise or whenever significant modifications are made to the facility or the temperature controlling equipment.”

GDP Guidelines Chapter 3.2.1
Read More

Who are the MHRA?

The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK. Recognised globally as an authority in its field, the agency plays a leading role in protecting and improving public health and supports innovation through scientific research and development. To find out more Click Here

MHRA responsibilities

The agency is responsible for:

• ensuring that medicines, medical devices and blood components for transfusion meet applicable standards of safety, quality and efficacy
• ensuring that the supply chain for medicines, medical devices and blood components is safe and secure
• promoting international standardisation and harmonisation to assure the effectiveness and safety of biological medicines
• helping to educate the public and healthcare professionals about the risks and benefits of medicines, medical devices and blood components, leading to safer and more effective use
• supporting innovation and research and development that’s beneficial to public health
• influencing UK, EU and international regulatory frameworks so that they’re risk-proportionate and effective at protecting public health

MHRA priorities

Some of the agency’s priorities from our 5-year Corporate Plan, 2018-2023, include:

• making our regulation more supportive of safe innovation
• supporting the government’s growth agenda through the life science strategy, which includes early access to medicines schemes and the adaptive licensing pilot
• introducing a combined reporting system for adverse incidents, medicines, medical devices, blood and counterfeit products under the established YC brand to ensure patient safety
• working with our partners across the UK, Europe and globally to prevent counterfeit and substandard products entering the supply chain
• establishing a centre of excellence for advanced therapies, including stem cells, at NIBSC
• increasing the volume of observational and interventional research, including clinical trials, using CPRD data
• engaging and networking more with healthcare professionals, patients and the public, including by working jointly with others in the health and social care system

In 2016 we published a Corporate Plan Refresh document to review and update the Agency’s strategic priorities halfway through the 2013-18 Corporate Plan period.

Every year our staff are invited to speak at conferences and other events around the world. Read our guide to booking MHRA speakers.

Taken from MHRA About Us Page